April 14, 2021

COVID-19 vaccine production: The European Commission issues a comfort letter on cooperation between companies in the supply chain

Thanks to Sofia D’Arena for collaborating on this article

On March 25, 2021, the European Commission (hereinafter, the “Commission”) issued a “comfort letter”[1] on the compliance of the “Matchmaking Event – Towards COVID-19 vaccines upscale production” (hereinafter, the “Matchmaking Event” or the “Event”) with EU competition law. In its letter the Commission addressed the compatibility of the exchange of commercial information with Article 101 of the Treaty on the Functioning of the European Union (TFEU). This is the second comfort letter on cooperation between competitors in the pharmaceutical sector that the Commission has publicly issued. On April 8, 2020, it also published a communication[2] setting out a temporary framework for assessing antitrust issues related to business cooperation in response to situations of urgency stemming from the current COVID-19 outbreak. The Italian Competition Authority (AGCM) issued a similar communication[3] shortly afterward (in May of the same year[4]).

The Matchmaking Event was aimed at encouraging participating companies to create new cooperation opportunities to address, to the best of their abilities, the bottlenecks in the current production and supply of COVID-19 vaccines.

The Event, which took place online on March 29 and 31, 2021, was co-organized by Ecorys Europe EEIG-GEIE, the main contractor and signatory for the consortium of the European Cluster Collaboration Platform (ECCP),[5] and SPI, a consortium partner responsible for operational organization (hereinafter, the “Co-organizers”). Notably, the Co-organizers organized the Matchmaking Event on behalf of the Commission as the host of the event.

Based on the comfort letter, the Matchmaking Event was intended for developers and manufacturers of vaccines to match demand with supply of potentially scarce inputs by exchanging confidential commercial information with the producers of relevant raw materials and other companies with relevant production capacity.

With its comfort letter, the Commission reassured participating firms that organization of and participation in the Matchmaking Event do not raise concerns under Art. 101 TFEU, provided that:

  • during private matchmaking meetings between participating firms (whether or not they are competitors), any exchange of confidential business information is limited to what is indispensable to address effectively the supply challenges linked to the COVID-19 pandemic;
  • during private matchmaking meetings with each other, direct competitors do not share any confidential or sensitive business information regarding their competing products (e.g., information about prices, discounts, costs, sales, strategies, expansion plans and investments, and customer lists) and they keep a record of the topics they do discuss;
  • if direct competitors do believe that exchange of the aforesaid confidential business information in relation to competing products is indispensable, they should contact the Commission for specific guidance at a specific address at least 24 hours before engaging in any such exchange in the context of the Matchmaking Event;
  • the Commission also requires the Co-organizers of the Matchmaking Event to keep a record of the companies that have met during the Event for the term of the contract,[6] and they must make it available to the Commission upon request.

Finally, the Commission reaffirmed its willingness to provide guidance to companies, associations, and their legal advisors on the implementation of cooperation initiatives of EU interest that are necessary to tackle the COVID-19 pandemic, but may raise concerns of compatibility with EU competition law.

[1] Available here.

[2] Available here.

[3] Available here.

[4] See our previous article on this topic in the June 2020 issue of our Life Sciences Newsletter here.

[5] Service contract with the Executive Agency for Small and Medium-sized Enterprises (EASME): ECCP, term of the contract December 9, 2019–December 8, 2021.

[6] Upon expiration of the contract, the Co-organizers shall transfer these data and records to DG GROW.

< Back to blog
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the life sciences and healthcare industry.
Read more
Our highly-ranked team of professionals will provide news, insights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and venture capital transactions.

March 20, 2023
Today, Regulation (EU) 2023/607 extending the transitional provisions for the placing on the market and putting into service of certain medical devices and in vitro diagnostic medical device...
January 31, 2023
Clinical trials: Ministry of Health signed off on decrees that (i) reorganize ethics committees and coordinate their activities, (ii) determine the single tariff for the authorization proced...
December 19, 2022
On 13 December 2022, EMA, European Commission and HMA jointly adopted a recommendation paper on the introduction of decentralised elements in the conduct of Clinical Trials in the EU/EEA
September 21, 2022
Payback for medical devices: Decree quantifying the exceeding of the expenditure ceiling for medical devices at national and regional level for the years 2015, 2016, 2017 and 2018 published ...
September 1, 2022
The 2021 annual law for market and competition addressing, as to the healthcare sector, reimbursement of drugs, intermediate distribution, patent linkage and institutional accreditation of p...
Search by...
Follow us on
Follow us on